Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact In case you missed it.. News from ESC Congress Rome 2016 ESC Hotline News PCSK9 inhibitor spares apheresis in severe heterozygous familial hypercholesterolaemia In this much discussed Hotline, treatment with alirocumab cut the need for lipoprotein apheresis treatments by 75% in this high risk group with inherited high cholesterol. More than 60% of patients treated with alirocumab no longer required apheresis. Apheresis treatment is costly, limited to few centres, and inconvenient for patients, who usually need to stay for most of the day during treatment. PCSK9 inhibitors may offer a cost effective alternative for these high risk patients. PCSK9 Forum News Editor Dr Peter Lansberg (Amsterdam Medical Centre, The Netherlands) discusses this study. Read the report and watch the video » Other News More reassurance on safety of very low LDL cholesterol levels on alirocumab Consistent benefit of PCSK9 inhibitors in high and very high risk patients; and in patients with multiple manifestations of cardiovascular disease New and updated edition of our popular therapeutic guide A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition. Read online » Download now » Forward to colleagues »   Questions & Answers Read the full answer and other questions on the PCSK9 Forum » Like us on Facebook For the latest updates, PCSK9 news and analysis. Follow us on Twitter Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts. Educational Partners and Supporters Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.